metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population
versus Standard of Care (SoC)
	durvalumab plus tremelimumab vs. Standard of Care (SoC)	1	1.04 [0.85; 1.27], 1 RCT, I2=0% inconclusive result	1.09 [0.90; 1.33], 1 RCT, I2=0% inconclusive result	-
mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative
versus durvalumab alone
	durvalumab plus tremelimumab vs. durvalumab alone	1	0.99 [0.69; 1.43], 1 RCT, I2=0% inconclusive result	1.13 [0.82; 1.56], 1 RCT, I2=0% inconclusive result	-
versus tremelimumab
	durvalumab plus tremelimumab vs. tremelimumab	1	0.72 [0.51; 1.02], 1 RCT, I2=0% inconclusive result	0.73 [0.53; 1.01], 1 RCT, I2=0% inconclusive result	-
mHNSCC - L2 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 positive